Index RUT
P/E -
EPS (ttm) -0.51
Insider Own 19.16%
Shs Outstand 116.86M
Perf Week 0.00%
Market Cap 534.11M
Forward P/E -
EPS next Y -0.38
Insider Trans 2.25%
Shs Float 94.69M
Perf Month -13.64%
Income -50.62M
PEG -
EPS next Q -0.16
Inst Own 59.11%
Short Float 5.81%
Perf Quarter -21.38%
Sales 34.16M
P/S 15.64
EPS this Y -14.95%
Inst Trans 0.72%
Short Ratio 11.18
Perf Half Y 1.56%
Book/sh 2.69
P/B 1.69
EPS next Y 35.67%
ROA -12.03%
Short Interest 5.51M
Perf Year 32.17%
Cash/sh 0.74
P/C 6.14
EPS next 5Y -
ROE -15.43%
52W Range 3.14 - 6.72
Perf YTD -26.09%
Dividend Est. -
P/FCF 763.02
EPS past 5Y -
ROI -15.04%
52W High -32.09%
Beta -0.05
Dividend TTM -
Quick Ratio 4.11
Sales past 5Y 13.92%
Gross Margin 44.37%
52W Low 45.22%
ATR (14) 0.18
Dividend Ex-Date -
Current Ratio 4.11
EPS Y/Y TTM -121.77%
Oper. Margin -202.63%
RSI (14) 36.91
Volatility 2.88% 3.29%
Employees 106
Debt/Eq 0.08
Sales Y/Y TTM -3.34%
Profit Margin -148.16%
Recom 1.00
Target Price 10.00
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q -292.72%
Payout -
Rel Volume 0.96
Prev Close 4.44
Sales Surprise -35.38%
EPS Surprise 1.75%
Sales Q/Q -86.36%
Earnings May 09 AMC
Avg Volume 492.37K
Price 4.56
SMA20 -6.81%
SMA50 -13.25%
SMA200 -14.18%
Trades
Volume 471,031
Change 2.70%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-29-23 Initiated
RBC Capital Mkts
Outperform
$6
Apr-21-23 Initiated
The Benchmark Company
Buy
$8
Apr-13-23 Initiated
Craig Hallum
Buy
$10
Feb-22-23 Initiated
Cowen
Outperform
$10
Feb-13-23 Initiated
H.C. Wainwright
Buy
$11
Dec-20-22 Initiated
Truist
Buy
$10
Dec-16-22 Initiated
Credit Suisse
Outperform
$13
Nov-29-22 Initiated
SVB Leerink
Outperform
$6
Nov-28-22 Initiated
Stifel
Buy
$12
May-01-24 08:00AM
Apr-22-24 08:00AM
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
08:27AM
Loading…
Feb-28-24 08:27AM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
09:00AM
Loading…
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
08:03AM
Loading…
May-14-23 08:03AM
May-11-23 10:55PM
(Thomson Reuters StreetEvents)
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GUSTAFSON KURT A Executive VP, Finance and CFO Apr 08 '24 Sale 5.27 6,954 36,648 176,697 Apr 09 06:38 PM Berkman Charles S Chief Legal Officer Apr 08 '24 Sale 5.27 6,954 36,648 292,617 Apr 09 06:37 PM GUSTAFSON KURT A Executive VP, Finance & CFO Apr 01 '24 Sale 5.46 11,849 64,696 170,110 Apr 02 06:30 PM FOEHR MATTHEW W President and CEO Mar 27 '24 Option Exercise 3.72 243,613 907,023 3,152,416 Mar 29 04:52 PM FOEHR MATTHEW W President and CEO Mar 22 '24 Buy 5.19 225,000 1,167,750 2,908,803 Mar 25 07:07 AM FOEHR MATTHEW W Chief Executive Officer Dec 12 '23 Buy 5.05 200,000 1,010,000 2,645,442 Dec 13 03:25 PM FOEHR MATTHEW W President and CEO Nov 10 '23 Buy 4.27 95,000 405,517 2,427,919 Nov 13 08:00 AM FOEHR MATTHEW W President and CEO Aug 14 '23 Buy 5.48 45,000 246,600 2,332,919 Aug 15 04:56 PM FOEHR MATTHEW W Chief Executive Officer Jun 09 '23 Buy 4.52 115,000 519,800 2,574,009 Jun 12 04:47 PM HIGGINS JOHN L Director May 23 '23 Option Exercise 3.68 9,000 33,120 2,471,686 May 25 04:45 PM HIGGINS JOHN L Director May 23 '23 Sale 4.05 9,000 36,450 2,462,686 May 25 04:45 PM HIGGINS JOHN L Director May 19 '23 Option Exercise 3.68 1,000 3,680 2,463,686 May 23 04:12 PM HIGGINS JOHN L Director May 19 '23 Sale 4.05 1,000 4,050 2,462,686 May 23 04:12 PM HIGGINS JOHN L Director May 18 '23 Option Exercise 3.68 50,000 184,000 2,512,686 May 19 05:03 PM HIGGINS JOHN L Director May 18 '23 Sale 3.89 50,000 194,500 2,462,686 May 19 05:03 PM FOEHR MATTHEW W Chief Executive Officer May 12 '23 Buy 3.40 440,000 1,496,000 2,438,414 May 15 04:02 PM
Index RUT
P/E -
EPS (ttm) -2.10
Insider Own 2.72%
Shs Outstand 61.00M
Perf Week 25.81%
Market Cap 1.48B
Forward P/E -
EPS next Y -2.94
Insider Trans -8.02%
Shs Float 59.97M
Perf Month 11.25%
Income -126.09M
PEG -
EPS next Q -0.83
Inst Own 101.70%
Short Float 10.37%
Perf Quarter 27.97%
Sales 168.34M
P/S 8.76
EPS this Y -66.34%
Inst Trans -2.45%
Short Ratio 8.94
Perf Half Y 38.89%
Book/sh 10.96
P/B 2.18
EPS next Y 15.08%
ROA -14.02%
Short Interest 6.22M
Perf Year -11.60%
Cash/sh 9.63
P/C 2.48
EPS next 5Y -
ROE -18.06%
52W Range 16.49 - 28.96
Perf YTD 12.72%
Dividend Est. -
P/FCF 22.13
EPS past 5Y -9.81%
ROI -16.98%
52W High -17.37%
Beta 0.77
Dividend TTM -
Quick Ratio 7.36
Sales past 5Y 70.11%
Gross Margin 93.17%
52W Low 45.12%
ATR (14) 1.19
Dividend Ex-Date -
Current Ratio 7.36
EPS Y/Y TTM -127.34%
Oper. Margin -81.54%
RSI (14) 69.54
Volatility 8.76% 4.95%
Employees 280
Debt/Eq 0.12
Sales Y/Y TTM 2.28%
Profit Margin -74.90%
Recom 1.46
Target Price 35.83
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q -56.17%
Payout -
Rel Volume 2.64
Prev Close 20.94
Sales Surprise -42.44%
EPS Surprise -192.45%
Sales Q/Q 106.80%
Earnings Feb 27 AMC
Avg Volume 696.01K
Price 23.93
SMA20 19.43%
SMA50 9.09%
SMA200 14.56%
Trades
Volume 1,840,673
Change 14.28%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-24 Reiterated
BTIG Research
Buy
$56 → $38
Feb-28-24 Downgrade
Piper Sandler
Overweight → Neutral
$37 → $24
May-19-23 Initiated
BofA Securities
Buy
$42
Dec-06-22 Initiated
Cowen
Outperform
Oct-13-22 Upgrade
Raymond James
Outperform → Strong Buy
$58
Sep-21-22 Initiated
JP Morgan
Overweight
$37
Jul-06-22 Resumed
Canaccord Genuity
Buy
$50
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$54
Jan-21-22 Initiated
SMBC Nikko
Outperform
$60
Dec-15-21 Initiated
H.C. Wainwright
Buy
$61
Oct-15-21 Resumed
BTIG Research
Buy
$56
Feb-24-21 Upgrade
Raymond James
Mkt Perform → Outperform
$58
Mar-04-20 Initiated
Barclays
Underweight
$28
Feb-25-20 Upgrade
Guggenheim
Neutral → Buy
$43
Jan-30-20 Initiated
RBC Capital Mkts
Outperform
$44
Nov-20-19 Resumed
Guggenheim
Neutral
Aug-07-19 Downgrade
Raymond James
Outperform → Mkt Perform
Aug-07-19 Downgrade
Guggenheim
Buy → Neutral
Jun-13-19 Initiated
Mizuho
Buy
Apr-12-19 Initiated
Guggenheim
Buy
Show Previous Ratings
Apr-09-24 08:01AM
Mar-08-24 05:01PM
Mar-07-24 05:00PM
Feb-28-24 04:01PM
09:35AM
(Thomson Reuters StreetEvents)
08:38AM
Loading…
08:38AM
Feb-27-24 05:20PM
04:39PM
04:26PM
(Associated Press Finance)
04:01PM
Feb-20-24 04:31PM
Feb-19-24 03:37AM
Feb-15-24 10:00AM
Jan-03-24 04:01PM
09:55AM
08:01AM
Loading…
Jan-02-24 08:01AM
Dec-30-23 05:02PM
Nov-21-23 04:01PM
Nov-09-23 02:19PM
Nov-08-23 05:21AM
(FierceBiotech.com) -7.01%
Nov-07-23 04:39PM
(Associated Press Finance)
04:01PM
04:01PM
Nov-03-23 12:01PM
Oct-31-23 04:01PM
12:00PM
Oct-26-23 08:01AM
Oct-17-23 04:21AM
Sep-27-23 09:01AM
Sep-19-23 04:01PM
06:01AM
Loading…
Aug-08-23 06:01AM
Aug-07-23 04:02PM
Aug-03-23 05:15PM
04:13PM
(Associated Press Finance)
04:01PM
Jul-27-23 08:01AM
Jul-03-23 08:38PM
Jun-21-23 08:00PM
Jun-18-23 10:00AM
May-30-23 06:01PM
May-09-23 01:49PM
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
04:08PM
04:01PM
May-01-23 04:01PM
Apr-26-23 08:00PM
08:01AM
Apr-17-23 01:31PM
Apr-09-23 01:19PM
Mar-14-23 04:31PM
02:56AM
Feb-28-23 05:10AM
Feb-25-23 07:17AM
Feb-23-23 05:25PM
04:01PM
Feb-20-23 10:00AM
Feb-16-23 04:01PM
Feb-07-23 04:01PM
Jan-26-23 02:33PM
Jan-09-23 08:01AM
Jan-05-23 06:30AM
Jan-04-23 04:01PM
Dec-12-22 03:44PM
10:00AM
Nov-30-22 09:55AM
Nov-25-22 12:00PM
Nov-10-22 04:01PM
09:55AM
09:01AM
Nov-07-22 05:25PM
04:01PM
04:01PM
Nov-03-22 09:01AM
Oct-31-22 04:01PM
Oct-28-22 11:58AM
Oct-14-22 09:41AM
Oct-06-22 08:37PM
Oct-05-22 08:01AM
Sep-09-22 08:01AM
Aug-29-22 06:35AM
Aug-03-22 05:25PM
04:01PM
Aug-02-22 06:30AM
Aug-01-22 11:31AM
Jul-27-22 04:01PM
Jul-01-22 11:59AM
May-26-22 05:01PM
May-13-22 09:18AM
May-07-22 09:30AM
May-06-22 10:24AM
05:38AM
May-05-22 05:25PM
04:01PM
11:26AM
11:12AM
11:07AM
09:31AM
08:45AM
May-04-22 10:52AM
May-03-22 07:55AM
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dahiyat Bassil I PRESIDENT & CEO Mar 11 '24 Sale 23.50 2,741 64,418 351,894 Mar 12 04:03 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 11 '24 Sale 23.50 1,280 30,082 186,433 Mar 12 04:05 PM Eckert Celia SVP, GENERAL COUNSEL Mar 11 '24 Sale 23.50 850 19,977 45,465 Mar 12 04:06 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 11 '24 Sale 23.50 849 19,953 121,070 Mar 12 04:08 PM GUSTAFSON KURT A Director Mar 06 '24 Option Exercise 10.73 15,000 160,950 20,007 Mar 07 04:10 PM GUSTAFSON KURT A Director Mar 06 '24 Sale 23.18 14,000 324,453 6,007 Mar 07 04:10 PM Dahiyat Bassil I PRESIDENT & CEO Mar 05 '24 Sale 23.43 12,528 293,519 300,097 Mar 07 04:01 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 05 '24 Sale 23.43 6,629 155,311 166,989 Mar 07 04:05 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 05 '24 Sale 23.43 4,474 104,821 121,919 Mar 07 04:07 PM Eckert Celia SVP, GENERAL COUNSEL Mar 05 '24 Sale 23.43 3,892 91,186 33,226 Mar 07 04:03 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 14 '24 Option Exercise 11.05 11,943 131,970 173,618 Feb 16 04:06 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Option Exercise 11.05 68,057 752,030 215,783 Feb 14 02:23 PM GORMAN KEVIN CHARLES Director Feb 13 '24 Buy 19.12 53 1,013 5,060 Feb 15 04:02 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Sale 19.38 54,108 1,048,743 161,675 Feb 14 02:23 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Option Exercise 11.05 65,001 718,261 357,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Sale 20.93 45,000 941,670 312,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Jun 21 '23 Option Exercise 4.25 76,012 323,051 325,713 Jun 22 08:33 AM Dahiyat Bassil I PRESIDENT & CEO Jun 21 '23 Sale 26.19 33,497 877,286 292,216 Jun 22 08:33 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite